Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Squalamine Lactate in Wet AMD
NCT00089830Phase 2Terminated
- Sponsor
- Genaera Corporation
- Start
- Aug 2004
- Modality
- Multivalent & Scaffold-Based Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of squalamine in exudative macular degeneration (3 arms), sponsored by Genaera Corporation. Primary endpoint: Proportion of patients with loss in best corrected visual acuity (BCVA) of greater than or equal to 15 letters at 52 weeks. Started Aug 2004; status: terminated.
02
Drugs
squalamine
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT00089830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00089830.